Skip to main content
Nectar Lifesciences Limited logo

Nectar Lifesciences Limited — Investor Relations & Filings

Ticker · NECLIFE ISIN · INE023H01027 LEI · 335800RY4LGC64KN9C05 BSE.NS Manufacturing
Open in API
Filings indexed 538 across all filing types
Latest filing 2026-06-01 Report Publication Anno…
Country IN India
Listing BSE.NS NECLIFE

About Nectar Lifesciences Limited

https://www.neclife.com/

Nectar Lifesciences Limited is a pharmaceutical organization specializing in the development and manufacturing of Active Pharmaceutical Ingredients (APIs) and finished dosage forms. The company maintains a significant focus on the cephalosporin segment, producing a wide range of oral and sterile products including Cefixime, Cefuroxime Axetil, and Ceftriaxone. Its operations encompass a fully integrated business model supported by large-scale manufacturing facilities that adhere to international regulatory standards such as USFDA and EUGMP. In addition to its core antibiotic portfolio, the company produces menthol and phytochemicals. Nectar Lifesciences serves a global clientele through contract manufacturing and development services, leveraging its research and development capabilities to provide high-quality therapeutic solutions across various international markets.

Recent filings

Filing Released Lang Actions
Please find attached herewith the copy of newspapers for publication of financial results of the Company for the quarter and financial year ended on March 31, 2026
Report Publication Announcement Classification · 85% confidence The document is a short letter from Nectar Lifesciences to the stock exchanges stating that the company’s financial results for the quarter and year ended March 31, 2026 have been published in newspapers. It does not contain the actual financial statements or substantive analysis, but simply notifies publication of the results. This matches the “Report Publication Announcement (RPA)” category.
2026-06-01 English
Copy of Newspaper Publication
Report Publication Announcement Classification · 85% confidence The document begins with a formal letter from Nectar Lifesciences to the National Stock Exchange and BSE dated June 1, 2026, stating that the company has published its quarterly and annual financial results in specified newspapers and is furnishing a newspaper copy for record. It does not contain the actual financial statements or analysis, but merely announces the publication of those results. Under the “Menu vs Meal” and report announcement rules, this constitutes a Report Publication Announcement rather than the report itself.
2026-06-01 English
Outcome of Board Meeting
Earnings Release Classification · 84% confidence The document is a formal SEBI LODR Regulation 33 announcement of audited standalone and consolidated financial results for the quarter and full year ended March 31, 2026, including auditors’ reports and board resolutions. This matches the definition of an Earnings Release—an initial, public release of periodic financial results—rather than a full annual report or other specific corporate action notice. FY 2026
2026-05-30 English
Financial Results for the Year 2025-26
Regulatory Filings Classification · 60% confidence The document is a formal disclosure to the stock exchanges under SEBI LODR Regulations (Reg. 30 & 33) announcing audited standalone and consolidated financial results for the year ended 31 March 2026, together with the outcome of a board meeting and auditors’ reports. It is not the company’s full annual report (10-K) with MD&A and governance chapters, nor a simple earnings highlight release (ER) or interim/quarterly report (IR). Instead, it is a regulatory announcement of results and board decisions filed to exchanges, which falls under the general Regulatory Filings category.
2026-05-30 English
Nectar Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve the Audited Financial Results ....
Regulatory Filings Classification · 80% confidence The document is a formal notice to stock exchanges informing of a scheduled Board Meeting to consider and approve audited financial results and financial statements. It is not the actual financial report, a proxy or AGM notice, nor a management change announcement. This is a general regulatory announcement under listing obligations. Therefore, it falls under the fallback category Regulatory Filings (RNS).
2026-05-25 English
General Updates
Capital/Financing Update Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the transfer of a business segment on a 'slump sale' basis. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations and provides an update on the extension of the expected completion date for the transaction. The content is an announcement about a capital transaction rather than a full financial report or detailed analysis. The document length is short (1941 characters), and it does not contain financial statements or detailed financial data. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as business transfers or slump sales.
2026-04-28 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.